Spyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Spyre Therapeutics

04/08/2026 22:21

Spyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -77 cents.  The mean expectation of fifteen analysts for the quarter was for a loss of 76 cents per share. Wall Street expected results to range from -100 cents to -49 cents per share.
Reported revenue was zero​; analysts expected zero. 
Spyre Therapeutics Inc's reported EPS for the quarter was a loss of 36 cents​.
The company reported a quarterly loss of $36.2 million.
Spyre Therapeutics Inc shares had risen by 6.9% this quarter and gained 189.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 8.5% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Spyre Therapeutics Inc is $105.00, about 9.6% above its last closing price of $94.93
This summary was machine generated from LSEG data August 4 at 09:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.76
-0.36
Beat
Mar. 31 2026 
-0.67
-0.74
Missed
Dec. 31 2025 
-0.77
-0.70
Beat
Sep. 30 2025 
-0.75
-0.15
Beat